$ACHC
Acadia Healthcare Company, Inc.

2013 Q1 Form 10-Q Financial Statement

#000119312513196184 Filed on May 02, 2013

View on sec.gov

Income Statement

Concept 2013 Q1 2012 Q1
Revenue $161.2M $89.56M
YoY Change 80.0% 431.66%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $114.3M $66.00M
YoY Change 73.18% 432.26%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $3.622M $1.610M
YoY Change 124.97% 705.0%
% of Gross Profit
Operating Expenses $154.5M $84.57M
YoY Change 82.66% 479.25%
Operating Profit
YoY Change
Interest Expense $8.762M $7.282M
YoY Change 20.32% -3741.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income $6.732M $4.992M
YoY Change 34.86% -1045.45%
Income Tax $2.678M $1.665M
% Of Pretax Income 39.78% 33.35%
Net Earnings $3.738M $3.679M
YoY Change 1.6% -1577.51%
Net Earnings / Revenue 2.32% 4.11%
Basic Earnings Per Share $0.07 $0.11
Diluted Earnings Per Share $0.07 $0.11
COMMON SHARES
Basic Shares Outstanding 49.91M shares 32.12M shares
Diluted Shares Outstanding 50.25M shares 32.33M shares

Balance Sheet

Concept 2013 Q1 2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $99.80M $800.0K
YoY Change 12375.0%
Cash & Equivalents $99.78M $840.0K
Short-Term Investments
Other Short-Term Assets $21.16M $17.60M
YoY Change 20.25%
Inventory
Prepaid Expenses
Receivables $78.78M $43.80M
Other Receivables $0.00 $0.00
Total Short-Term Assets $212.3M $62.20M
YoY Change 241.31%
LONG-TERM ASSETS
Property, Plant & Equipment $268.5M $98.30M
YoY Change 173.17%
Goodwill $565.6M
YoY Change
Intangibles $16.25M
YoY Change
Long-Term Investments
YoY Change
Other Assets $22.52M $21.90M
YoY Change 2.84%
Total Long-Term Assets $872.9M $391.1M
YoY Change 123.19%
TOTAL ASSETS
Total Short-Term Assets $212.3M $62.20M
Total Long-Term Assets $872.9M $391.1M
Total Assets $1.085B $453.3M
YoY Change 139.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $20.12M $8.100M
YoY Change 148.35%
Accrued Expenses $17.45M $30.70M
YoY Change -43.15%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $9.555M $8.000M
YoY Change 19.44%
Total Short-Term Liabilities $70.77M $46.70M
YoY Change 51.54%
LONG-TERM LIABILITIES
Long-Term Debt $560.1M $299.5M
YoY Change 87.01%
Other Long-Term Liabilities $13.63M $6.300M
YoY Change 116.32%
Total Long-Term Liabilities $573.7M $305.8M
YoY Change 87.61%
TOTAL LIABILITIES
Total Short-Term Liabilities $70.77M $46.70M
Total Long-Term Liabilities $573.7M $305.8M
Total Liabilities $648.3M $352.6M
YoY Change 83.87%
SHAREHOLDERS EQUITY
Retained Earnings -$20.44M
YoY Change
Common Stock $500.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $436.9M $100.7M
YoY Change
Total Liabilities & Shareholders Equity $1.085B $453.3M
YoY Change 139.39%

Cashflow Statement

Concept 2013 Q1 2012 Q1
OPERATING ACTIVITIES
Net Income $3.738M $3.679M
YoY Change 1.6% -1577.51%
Depreciation, Depletion And Amortization $3.622M $1.610M
YoY Change 124.97% 705.0%
Cash From Operating Activities $941.0K $4.935M
YoY Change -80.93% 722.5%
INVESTING ACTIVITIES
Capital Expenditures $12.76M $3.911M
YoY Change 226.36% -588.88%
Acquisitions $22.38M $90.40M
YoY Change -75.25%
Other Investing Activities $133.0K -$88.00K
YoY Change -251.14%
Cash From Investing Activities -$35.27M -$94.22M
YoY Change -62.57% 11677.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 85.48M 29.01M
YoY Change 194.66% -7352.5%
NET CHANGE
Cash From Operating Activities 941.0K 4.935M
Cash From Investing Activities -35.27M -94.22M
Cash From Financing Activities 85.48M 29.01M
Net Change In Cash 51.15M -60.28M
YoY Change -184.86% 9946.33%
FREE CASH FLOW
Cash From Operating Activities $941.0K $4.935M
Capital Expenditures $12.76M $3.911M
Free Cash Flow -$11.82M $1.024M
YoY Change -1254.59% -26.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9487500 shares
CY2013Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
50455786 shares
CY2012Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
15.50
CY2012Q4 us-gaap Common Stock Discount On Shares
CommonStockDiscountOnShares
7300000
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
840000
CY2011Q4 us-gaap Long Term Debt
LongTermDebt
150000000
CY2012Q2 us-gaap Common Stock Discount On Shares
CommonStockDiscountOnShares
7400000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
22.50
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1050000 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8528000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.90
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2013Q1 us-gaap Other Assets Current
OtherAssetsCurrent
21164000
CY2013Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
23647000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
2700000 shares
CY2013Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12750 shares
CY2013Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3432000
CY2013Q1 us-gaap Liabilities Current
LiabilitiesCurrent
70770000
CY2013Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
0
CY2013Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20439000
CY2013Q1 us-gaap Assets
Assets
1085177000
CY2013Q1 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
99600000
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99775000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.74
CY2013Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
78780000
CY2013Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
600000
CY2013Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
14277000
CY2013Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
10998000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
883372 shares
CY2013Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
284970000
CY2013Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
22521000
CY2013Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
800000
CY2013Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
3822000
CY2013Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1085177000
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49964426 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
476978 shares
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
500000
CY2013Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1462000
CY2013Q1 us-gaap Goodwill
Goodwill
565586000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
204821 shares
CY2013Q1 us-gaap Liabilities
Liabilities
648318000
CY2013Q1 achc Intangible Assets Gross Carrying Amount
IntangibleAssetsGrossCarryingAmount
17709000
CY2013Q1 achc Indefinite Lived Intangible Assets Excluding Goodwill Accumulated Amortization
IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedAmortization
CY2013Q1 us-gaap Long Term Debt
LongTermDebt
569653000
CY2013Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
16247000
CY2013Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
300000
CY2013Q1 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
12573000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
21.48
CY2013Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17452000
CY2013Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
14.00
CY2013Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
268531000
CY2013Q1 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
21 State
CY2013Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
9555000
CY2013Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49964426 shares
CY2013Q1 us-gaap Assets Current
AssetsCurrent
212292000
CY2013Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
456798000
CY2013Q1 us-gaap Business Acquisition Contingent Consideration At Fair Value
BusinessAcquisitionContingentConsiderationAtFairValue
6120000
CY2013Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
500000
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16439000
CY2013Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
560098000
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
436859000
CY2013Q1 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
1.00 pure
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4065000
CY2013Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
13628000
CY2013Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
20116000
CY2013Q1 achc Behavioral Healthcare Facilities
BehavioralHealthcareFacilities
44 Facility
CY2013Q1 achc Aggregate Number Of Psychiatric Beds
AggregateNumberOfPsychiatricBeds
3500 Beds
CY2013Q1 achc Intangible Assets Accumulated Amortization Carrying Amount
IntangibleAssetsAccumulatedAmortizationCarryingAmount
1462000
CY2013Q1 achc Business Acquisition Contingent Consideration Carrying Amount
BusinessAcquisitionContingentConsiderationCarryingAmount
6120000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
947000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61118000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.74
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
346821 shares
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
138321 shares
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
9.40
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5632000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.63
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2012Q4 us-gaap Other Assets Current
OtherAssetsCurrent
16332000
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
28749000
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2012Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3432000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
71851000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24177000
CY2012Q4 us-gaap Assets
Assets
983413000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49399000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.13
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
63870000
CY2012Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
13815000
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
7484000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
555097 shares
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
249972000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
32100000
CY2012Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
998000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
983413000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49887300 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
318063 shares
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
499000
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1259000
CY2012Q4 us-gaap Goodwill
Goodwill
557402000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
164062 shares
CY2012Q4 us-gaap Liabilities
Liabilities
550863000
CY2012Q4 us-gaap Long Term Debt
LongTermDebt
473318000
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15988000
CY2012Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
11380000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
15.73
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16341000
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
236942000
CY2012Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7680000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49887300 shares
CY2012Q4 us-gaap Assets Current
AssetsCurrent
140981000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
456228000
CY2012Q4 us-gaap Business Acquisition Contingent Consideration At Fair Value
BusinessAcquisitionContingentConsiderationAtFairValue
6120000
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13030000
CY2012Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
465638000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
432550000
CY2012Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2707000
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
12376000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
19081000
CY2012Q4 achc Intangible Assets Gross Carrying Amount
IntangibleAssetsGrossCarryingAmount
17247000
CY2012Q4 achc Indefinite Lived Intangible Assets Excluding Goodwill Accumulated Amortization
IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedAmortization
CY2012Q4 achc Intangible Assets Accumulated Amortization Carrying Amount
IntangibleAssetsAccumulatedAmortizationCarryingAmount
1259000
CY2012Q4 achc Business Acquisition Contingent Consideration Carrying Amount
BusinessAcquisitionContingentConsiderationCarryingAmount
6120000
CY2012Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
700000
CY2012Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
139000000
CY2012Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1000000
CY2012Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
172800000
CY2012 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
124194 shares
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.01
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
429498 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.04
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
97028 shares
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y7M2D
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M18D
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
9.40
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.36
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M11D
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.012 pure
CY2013Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2013Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013Q1 dei Document Type
DocumentType
10-Q
CY2013Q1 dei Document Period End Date
DocumentPeriodEndDate
2013-03-31
CY2013Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001520697
CY2013Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013Q1 dei Trading Symbol
TradingSymbol
ACHC
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.42 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
96321 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
42107 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
318170 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
14.70
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.93
CY2012 achc Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P4Y6M
CY2012 achc Share Based Compensation Arrangement By Share Based Payment Award Rollover Options Issued In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardRolloverOptionsIssuedInPeriodWeightedAverageRemainingContractualTerm
P9Y2M19D
CY2012 achc Share Based Compensation Arrangement By Share Based Payment Award Rollover Options Issued In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardRolloverOptionsIssuedInPeriodIntrinsicValue
2960000
CY2012 achc Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue
14.25
CY2012 achc Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodAggregateIntrinsicValue
CY2013Q1 dei Entity Registrant Name
EntityRegistrantName
Acadia Healthcare Company, Inc.
CY2013Q1 dei Amendment Flag
AmendmentFlag
false
CY2013Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2013Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
15500000
CY2013Q1 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
161213000
CY2013Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
21375 shares
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3622000
CY2013Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
133000
CY2013Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.01
CY2013Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
22375000
CY2013Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
850000
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35272000
CY2013Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
4153000
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.95
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
356400 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
29.09
CY2013Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49911000 shares
CY2013Q1 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
43330000
CY2013Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
52500000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
6750 shares
CY2013Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-15000
CY2013Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.01
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y4M10D
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2013Q1 us-gaap Goodwill Other Changes
GoodwillOtherChanges
654000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
15.73
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9522000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
348000
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
601000
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
29.22
CY2013Q1 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
165106000
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
434000
CY2013Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
4492000
CY2013Q1 us-gaap Proceeds And Excess Tax Benefit From Sharebased Compensation
ProceedsAndExcessTaxBenefitFromSharebasedCompensation
635000
CY2013Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3622000
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
50376000
CY2013Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.08
CY2013Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2013Q1 us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="3%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>1.</b></font></td> <td valign="top" width="1%"><font size="1">&#xA0;</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Description of Business and Basis of Presentation</b></font></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Description of Business</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Acadia Healthcare Company, Inc. (the &#x201C;Company&#x201D;) develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States. At March&#xA0;31, 2013, the Company operated 44 behavioral healthcare facilities with approximately 3,500 licensed beds in 21 states.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Basis of Presentation</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The business of the Company is conducted through limited liability companies and C-corporations, each of which is a direct or indirect wholly-owned subsidiary of the Company. The Company&#x2019;s consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, all of which are 100% owned. All significant intercompany accounts and transactions have been eliminated in consolidation.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201C;GAAP&#x201D;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation of our financial position and results of operations have been included. The Company&#x2019;s fiscal year ends on December&#xA0;31 and interim results are not necessarily indicative of results for a full year or any other interim period. The condensed consolidated balance sheet at December&#xA0;31, 2012 has been derived from the audited financial statements as of that date. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s consolidated financial statements and notes thereto for the fiscal year ended December&#xA0;31, 2012 included in the Company&#x2019;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March&#xA0;1, 2013. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Certain reclassifications have been made to prior years to conform to the current year presentation.</font></p> </div>
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M26D
CY2013Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
16983000
CY2013Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2455000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
3738000
CY2013Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
8838000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011 pure
CY2013Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
4054000
CY2013Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2013Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-7491000
CY2013Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50250000 shares
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
85481000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.41 pure
CY2013Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
339000 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
40385 shares
CY2013Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2013Q1 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-267000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
15.60
CY2013Q1 us-gaap Tax Benefit From Stock Options Exercised1
TaxBenefitFromStockOptionsExercised1
200000
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2678000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
6000 shares
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
154481000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
205300 shares
CY2013Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-997000
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12764000
CY2013Q1 us-gaap Line Of Credit Facility Increase Additional Borrowings
LineOfCreditFacilityIncreaseAdditionalBorrowings
50000000
CY2013Q1 us-gaap Health Care Organization Medical Supplies And Drugs Expense
HealthCareOrganizationMedicalSuppliesAndDrugsExpense
8598000
CY2013Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-316000
CY2013Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
150000000
CY2013Q1 us-gaap Professional Fees
ProfessionalFees
9014000
CY2013Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
133000
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6732000
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
600000 shares
CY2013Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2327000
CY2013Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
94351000
CY2013Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-271000
CY2013Q1 us-gaap Severance Costs
SeveranceCosts
469000
CY2013Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
1875000
CY2013Q1 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
9271000
CY2013Q1 us-gaap Interest Expense
InterestExpense
8762000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.51
CY2013Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-9350000
CY2013Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
1072000
CY2013Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1474000
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
167000
CY2013Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.08
CY2013Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
540000
CY2013Q1 achc Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P9Y11M27D
CY2013Q1 achc Share Based Compensation Arrangement By Share Based Payment Award Rollover Options Issued In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardRolloverOptionsIssuedInPeriodIntrinsicValue
61000
CY2013Q1 achc Aggregate Intrinsic Value Of Restricted Stock Units Vested
AggregateIntrinsicValueOfRestrictedStockUnitsVested
400000
CY2013Q1 achc Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue
16.17
CY2013Q1 achc Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Income Taxes
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeIncomeTaxes
6556000
CY2013Q1 achc Capitalized Cost Incurred
CapitalizedCostIncurred
100000
CY2013Q1 achc Health Care Organization Revenue Before Provision For Doubtful Accounts
HealthCareOrganizationRevenueBeforeProvisionForDoubtfulAccounts
165705000
CY2013Q1 achc Legal Accounting And Other Fees
LegalAccountingAndOtherFees
1005000
CY2013Q1 achc Payment Of Debt Redemption Premium
PaymentOfDebtRedemptionPremium
6759000
CY2013Q1 achc Share Based Compensation Arrangement By Share Based Payment Award
ShareBasedCompensationArrangementByShareBasedPaymentAward
0.25 pure
CY2013Q1 achc Share Based Compensation Arrangement By Share Based Payment Stock Options Granted Term
ShareBasedCompensationArrangementByShareBasedPaymentStockOptionsGrantedTerm
P10Y
CY2013Q1 achc Deposits Related To Acquisition
DepositsRelatedToAcquisition
11684000
CY2013Q1 achc Weighted Average Vesting Period
WeightedAverageVestingPeriod
P1Y9M
CY2013Q1 achc Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodAggregateIntrinsicValue
CY2012Q1 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
7000000
CY2012Q1 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
89563000
CY2012Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1610000
CY2012Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
58000
CY2012Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.01
CY2012Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
90400000
CY2012Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
50000
CY2012Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-94223000
CY2012Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1048000
CY2012Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
331535 shares
CY2012Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32120000 shares
CY2012Q1 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
93131000
CY2012Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.01
CY2012Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4686000
CY2012Q1 us-gaap Share Based Compensation
ShareBasedCompensation
578000
CY2012Q1 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
146101000
CY2012Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
5417000
CY2012Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1705000
CY2012Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1610000
CY2012Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-60278000
CY2012Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-19000
CY2012Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.11
CY2012Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
8981000
CY2012Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1546000
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
3679000
CY2012Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
3327000
CY2012Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
CY2012Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1244000
CY2012Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32333000 shares
CY2012Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29010000
CY2012Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
213000 shares
CY2012Q1 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
1775000
CY2012Q1 us-gaap Operating Expenses
OperatingExpenses
84571000
CY2012Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-88000
CY2012Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4992000
CY2012Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
400000 shares
CY2012Q1 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
2731000
CY2012Q1 us-gaap Interest Expense
InterestExpense
7282000
CY2012Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
714000
CY2012Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
695000
CY2012Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4935000
CY2012Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2242000
CY2012Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
55143000
CY2012Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
960000
CY2012Q1 us-gaap Severance Costs
SeveranceCosts
6000
CY2012Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
2000000
CY2012Q1 us-gaap Tax Benefit From Stock Options Exercised1
TaxBenefitFromStockOptionsExercised1
0
CY2012Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1665000
CY2012Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3484000
CY2012Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3911000
CY2012Q1 us-gaap Health Care Organization Medical Supplies And Drugs Expense
HealthCareOrganizationMedicalSuppliesAndDrugsExpense
4445000
CY2012Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.10
CY2012Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2012Q1 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-482000
CY2012Q1 us-gaap Professional Fees
ProfessionalFees
4173000
CY2012Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.10
CY2012Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
587000
CY2012Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
352000
CY2012Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
25000000
CY2012Q1 achc Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Income Taxes
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeIncomeTaxes
9931000
CY2012Q1 achc Capitalized Cost Incurred
CapitalizedCostIncurred
100000
CY2012Q1 achc Health Care Organization Revenue Before Provision For Doubtful Accounts
HealthCareOrganizationRevenueBeforeProvisionForDoubtfulAccounts
91268000
CY2012Q1 achc Legal Accounting And Other Fees
LegalAccountingAndOtherFees
689000

Files In Submission

Name View Source Status
0001193125-13-196184-index-headers.html Edgar Link pending
0001193125-13-196184-index.html Edgar Link pending
0001193125-13-196184.txt Edgar Link pending
0001193125-13-196184-xbrl.zip Edgar Link pending
achc-20130331.xml Edgar Link completed
achc-20130331.xsd Edgar Link pending
achc-20130331_cal.xml Edgar Link unprocessable
achc-20130331_def.xml Edgar Link unprocessable
achc-20130331_lab.xml Edgar Link unprocessable
achc-20130331_pre.xml Edgar Link unprocessable
d513520d10q.htm Edgar Link pending
d513520dex103.htm Edgar Link pending
d513520dex104.htm Edgar Link pending
d513520dex311.htm Edgar Link pending
d513520dex312.htm Edgar Link pending
d513520dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending